AVEO Oncology, an LG Chem company, Announces Three Poster Presentations at ASCO 2025 Annual Meeting

On April 28, 2025 AVEO Oncology, an LG Chem company ("AVEO"), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, reported that three abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2025 annual meeting this May 30-June 3, 2025, in Chicago, IL (Press release, AVEO, APR 28, 2025, View Source [SID1234652269]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title: Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study
First Author: Alexander Chehrazi-Raffle, MD, City of Hope Cancer Center
Abstract Number: 4540
Poster Session: Genitourinary Cancer—Kidney and Bladder
Poster Board: 340
Date and Time: Monday, June 2, 2025, 9:00am – 12:00 PM CDT

Title: FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET Mab) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC)
First Author: Julie E. Bauman, MD, MPH, George Washington University Cancer Center
Abstract Number: TPS6115
Poster Session: Head and Neck Cancer
Poster Board: 520a
Date and Time: Monday, June 2, 2025, 9:00 AM – 12:00 PM CDT

Title: A phase1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia
First Author: Eric Roeland, MD, FAAHPM, Oregon Health & Science University
Abstract Number: TPS12142
Poster Session: Symptom Science and Palliative Care
Poster Board: 159a
Date and Time: Monday, June 2, 2025, 1:30-4:30 PM CDT